Markets
Stocks
Mutual Funds & ETF's
Sectors
Tools
Overview
Market News
Currencies
International
Search InvestCenter
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Top Indices
DJI
Nasdaq Composite
SPX
My Portfolio
Pfizer
(NY:
PFE
)
29.22
-0.05 (-0.17%)
Official Closing Price
Updated: 7:00 PM EDT, Oct 18, 2024
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
All News about Pfizer
< Previous
1
2
...
28
29
30
31
32
33
34
35
36
...
99
100
Next >
Unpacking the Latest Options Trading Trends in Pfizer
February 12, 2024
Via
Benzinga
2 Value Stocks With Monster Yields
February 12, 2024
These two low-priced large-cap stocks sport ginormous yields.
Via
The Motley Fool
7 Dividend Stocks to Buy at a 52-Week Low
February 12, 2024
Each of these dividend stocks has been down sharply in the last 12 months but has fundamental reasons that support a turnaround.
Via
InvestorPlace
3 Doomed Biotech Stocks to Dump Before They Dive: February 2024
February 11, 2024
Spot the looming risks in the biotech sector and avoid these three doomed biotech stocks likely to burn shareholder value significantly.
Via
InvestorPlace
2 Bargain Basement Stocks to Buy Now and Hold Forever
February 11, 2024
These beaten-down stocks could present an opportunity to long-term investors.
Via
The Motley Fool
Want an Extra $100 in Annual Dividend Income? Invest $1,340 in These 3 High-Yield Dividend Stocks.
February 11, 2024
With an average yield of 7.5%, about $1,340 is all it takes to secure $100 worth of annual dividend payments from these high-yield stocks.
Via
The Motley Fool
System1 Group Revolutionizes Ads for Maximum Impact in 2024
February 10, 2024
--News Direct--
Via
News Direct
System1 Group Revolutionizes Ads for Maximum Impact in 2024
February 10, 2024
James Gregory, the CEO of System1 Group Plc joins Steve Darling from Proactive to provide insights into the company's unique approach to advertising. System1 Group aims to assist the world's largest...
Via
TheNewswire.com
ROSEN, NATIONAL INVESTOR COUNSEL, Encourages BioNTech SE Investors to Secure Counsel Before Important Deadline in Securities Class Action - BNTX
February 09, 2024
Search for the latest press releases from publicly traded companies, private corporations, non-profits and other public sector organizations.
Via
NewMediaWire
Topics
Lawsuit
Exposures
COVID-19
Financial
Legal
ROSEN, NATIONAL INVESTOR COUNSEL, Encourages BioNTech SE Investors to Secure Counsel Before Important Deadline in Securities Class Action - BNTX
February 09, 2024
WHY: NEW YORK, NY - (NewMediaWire) - February 09, 2024 - Rosen Law Firm, a global investor rights law firm, reminds purchasers of securities of BioNTech SE (NASDAQ: BNTX) between March 30, 2022 and...
Via
TheNewswire.com
Topics
Lawsuit
Exposures
COVID-19
Financial
Legal
Why Is Moderna Stock Trading Lower Today?
February 09, 2024
Moderna long term data indicates a faster decline in efficacy for its RSV vaccine than the RSV vaccines from GSK and Pfizer.
Via
Benzinga
S&P 500 rockets to new highs as earnings beat estimates
February 09, 2024
The S&P 500 hits new highs as 10 of the 11 S&P sectors report positive Q4 earnings surprises. The tech and energy sectors are among the earnings leaders.
Via
MarketBeat
Topics
ETFs
Earnings
Stocks
Exposures
Financial
US Equities
3 Blue-Chip Stocks to Buy for High Total Returns by 2025
February 08, 2024
These undervalued blue-chip stocks represent fundamentally strong companies with healthy cash flow visibility.
Via
InvestorPlace
3 Value Stocks to Buy at 52-Week Low in February
February 07, 2024
Optimistic in 2024? Here are three of the best value stocks amid the market's cautious revival, offering strong upside potential.
Via
InvestorPlace
3 Blue-Chip Stocks to Buy at a 52-Week Low in February
February 07, 2024
Higher-for-longer interest rates and undervalued metrics make it a good time to look for blue-chip stocks at a low price.
Via
InvestorPlace
Pfizer's Problems Go Far Beyond Just Declining COVID Revenue
February 07, 2024
Can Pfizer's stock bounce back?
Via
The Motley Fool
Exposures
COVID-19
2024 Promises To Bring Pharmaceutical Breakthroughs On The Oncology Front
February 07, 2024
On Thursday, Merck & Co Inc (NYSE: MRK) topped estimates with its fourth quarter revenue and adjusted earnings fueled by its blockbuster cancer drug Keytruda, along with HPV prevention vaccine...
Via
Benzinga
Want to Earn $2,000 in Annual Dividend Income? Invest $33,000 in These 3 Stocks.
February 07, 2024
These dividend stocks haven't been great performers over the past year, but they could be excellent investments to buy and hold for the long run.
Via
The Motley Fool
3 Biotech Stocks to Buy on the Dip: February 2024
February 07, 2024
Here are three biotech stocks to buy that are trading at prices that may not account for potential breakthrough opportunities
Via
InvestorPlace
Want to Get Richer? Here Are the 3 Best Stocks to Buy Now and Hold Forever
February 07, 2024
Healthcare is an excellent place to find some tried and true wealth compounders.
Via
The Motley Fool
7 Retirement Stocks to Buy at 52-Week Lows
February 06, 2024
Markets may be at historic highs, but there are still plenty of high-quality retirement stocks to buy today at compelling valuations.
Via
InvestorPlace
Topics
Retirement
Exposures
Pension
GeoVax Reports Positive Interim Data From Phase 2 Clinical Trial of GEO-CM04S1 as a Universal Covid-19 Vaccine Booster
February 06, 2024
Search for the latest press releases from publicly traded companies, private corporations, non-profits and other public sector organizations.
Via
NewMediaWire
Exposures
COVID-19
GeoVax Reports Positive Interim Data From Phase 2 Clinical Trial of GEO-CM04S1 as a Universal Covid-19 Vaccine Booster
February 06, 2024
Results Demonstrate Potential Protective Immunity Against Multiple SARS-CoV-2 Variants
Via
TheNewswire.com
Exposures
COVID-19
3 Reliable Dividend Stocks With Yields Above 6% That You Can Buy for Less Than $100 Right Now
February 06, 2024
You don't have to already be rich to start building a significant passive income stream.
Via
The Motley Fool
Arvinas and Pfizer’s Vepdegestrant (ARV-471) Receives FDA Fast Track Designation for the Treatment of Patients with ER+/HER2- Metastatic Breast Cancer
February 06, 2024
From
Arvinas Inc.
Via
GlobeNewswire
The 7 Best Healthcare Stocks to Invest In for Big Gains in 2024
February 06, 2024
Invest in the future with healthcare stocks 2024; offering a blend of market stability and cutting-edge medical advancements.
Via
InvestorPlace
3 Magnificent Ultra-High-Yield Dividend Stocks That Are Screaming Buys in February
February 06, 2024
These high-octane income stocks, which sport an average yield of 7.34%, can pad patient investors' pocketbooks.
Via
The Motley Fool
3 Sleeper Stocks to Buy for the Next Bull Run: February 2024
February 05, 2024
Embark on a savvy investing as we uncover three sleeper stocks and chart their stellar long-term potential to perform.
Via
InvestorPlace
3 Magnificent Stocks to Buy on the Dip: February 2024
February 05, 2024
Although the market doesn’t seem to appreciate these stocks to buy on dip, it’s missing out on potentially robust opportunities.
Via
InvestorPlace
NVO, LLY or AZN: Which Pharma Stock Is the Best Weight-Loss Investment?
February 05, 2024
The relaunch of Wegovy last year caused a mad dash by weight loss stocks to compete for market leadership in anti-obesity drugs.
Via
InvestorPlace
< Previous
1
2
...
28
29
30
31
32
33
34
35
36
...
99
100
Next >
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.